• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服普萘洛尔、美托洛尔、阿替洛尔和索他洛尔的单剂量动力学:与亲脂性的关系。

Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.

作者信息

Ochs H R, Greenblatt D J, Arendt R M, Schäfer-Korting M, Mutschler E

出版信息

Arzneimittelforschung. 1985;35(10):1580-2.

PMID:2866772
Abstract

Nine healthy volunteers received single oral doses of the following four beta-adrenergic blocking agents: propranolol (160 mg), metoprolol (100 mg), atenolol (200 mg), and sotalol (320 mg). The kinetics of each drug were determined from multiple serum concentrations measured during 24-48 h after each dose, and in vitro lipid solubility determined using the liquid chromatographic (HPLC) retention index. Oral clearance for the four drugs ranged from 40.2 ml/min/kg for propranolol down to 2.1 for sotalol. Oral clearance was highly correlated (r = 0.99) with in vitro lipid solubility, with propranolol being the most lipophilic drug and sotalol the least. Thus lipophilicity is a physicochemical property of beta-adrenergic blockers that appears to influence their intrinsic clearance after oral dosage.

摘要

九名健康志愿者分别单次口服以下四种β-肾上腺素能阻滞剂:普萘洛尔(160毫克)、美托洛尔(100毫克)、阿替洛尔(200毫克)和索他洛尔(320毫克)。每种药物的动力学通过在每次给药后24至48小时内多次测量血清浓度来确定,体外脂溶性则使用液相色谱(HPLC)保留指数来测定。四种药物的口服清除率范围从普萘洛尔的40.2毫升/分钟/千克到索他洛尔的2.1毫升/分钟/千克。口服清除率与体外脂溶性高度相关(r = 0.99),普萘洛尔是最具亲脂性的药物,而索他洛尔亲脂性最低。因此,亲脂性是β-肾上腺素能阻滞剂的一种物理化学性质,似乎会影响其口服给药后的内在清除率。

相似文献

1
Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.口服普萘洛尔、美托洛尔、阿替洛尔和索他洛尔的单剂量动力学:与亲脂性的关系。
Arzneimittelforschung. 1985;35(10):1580-2.
2
Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.不同亲脂性β受体阻滞剂(普萘洛尔、美托洛尔、索他洛尔、阿替洛尔)在大鼠单次及多次给药后血浆和组织中的时辰药代动力学。
Naunyn Schmiedebergs Arch Pharmacol. 1985 Jul;330(1):42-9. doi: 10.1007/BF00586708.
3
Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol.普萘洛尔、醋丁洛尔和索他洛尔的药代动力学、中枢神经系统摄取及脂溶性
Cardiology. 1984;71(6):307-14. doi: 10.1159/000173684.
4
[Comparative pharmacokinetics of beta-blockers].[β受体阻滞剂的比较药代动力学]
Nouv Presse Med. 1978 Sep 20;7(31):2685-7.
5
Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.硝苯地平对普萘洛尔、美托洛尔和阿替洛尔药代动力学及药效学影响的研究。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):29S-35S. doi: 10.1111/j.1365-2125.1984.tb02425.x.
6
Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.β-肾上腺素受体阻断药在甲状腺疾病中的临床药代动力学
Clin Pharmacokinet. 1983 Jan-Feb;8(1):1-16. doi: 10.2165/00003088-198308010-00001.
7
Formation of the N-nitroso derivatives of six beta-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes.六种β-肾上腺素能阻滞剂的N-亚硝基衍生物的形成及其对大鼠和人肝细胞的遗传毒性作用。
Cancer Res. 1991 May 1;51(9):2273-9.
8
Elimination of beta-blockers in sewage treatment plants.污水处理厂中β受体阻滞剂的去除。
Water Res. 2007 Apr;41(7):1614-22. doi: 10.1016/j.watres.2007.01.004. Epub 2007 Feb 15.
9
A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.阿替洛尔、美托洛尔、氧烯洛尔和普萘洛尔在老年高血压患者和年轻健康受试者体内的药代动力学比较。
Br J Clin Pharmacol. 1985 Oct;20(4):327-31. doi: 10.1111/j.1365-2125.1985.tb05072.x.
10
Beta-blocker brain concentrations in man.人体中β受体阻滞剂的脑内浓度。
Eur J Clin Pharmacol. 1985;28 Suppl:21-3. doi: 10.1007/BF00543705.

引用本文的文献

1
Informing a Comprehensive Risk Assessment of Infant Drug Exposure From Human Milk: Application of a Physiologically Based Pharmacokinetic Lactation Model for Sotalol.从人乳中告知婴儿药物暴露的综合风险评估:索他洛尔生理基于药代动力学的泌乳模型的应用。
J Clin Pharmacol. 2023 Jun;63 Suppl 1:S106-S116. doi: 10.1002/jcph.2242.
2
Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.基于生理学的药代动力学模型在预测整个儿科年龄范围内口服药物暴露中的应用——以索他洛尔为模型药物。
AAPS J. 2014 Mar;16(2):226-39. doi: 10.1208/s12248-013-9555-6. Epub 2014 Jan 8.
3
Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
索他洛尔。其药理特性及在心律失常治疗应用中的最新综述。
Drugs. 1993 Oct;46(4):678-719. doi: 10.2165/00003495-199346040-00007.
4
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.索他洛尔。对其药效学和药代动力学特性以及治疗用途的综述。
Drugs. 1987 Sep;34(3):311-49. doi: 10.2165/00003495-198734030-00002.